DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ambrisentan
Ambrisentan
Endothelin System and Therapeutic Application of Endothelin Receptor
4 Tier)
Summary of Appeals & Independent Review Organization
Ambrisentan (Letairis®) Issued by PHA’S Scientific Leadership Council Information Is Based on the United States Food and Drug Administration Drug Labeling
Ambrisentan (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16 Last Review Date: 06/16 Revision Log
Therapeutic Classes Additions (Preferred) Removals (Non-Preferred)
84 November 2008 Produced by NHS Tayside Drug and Therapeutics Committee Medicines Advisory Group (MAG)
List of Formulary Drug Removals
Pennsylvania Department of Human Services Statewide Preferred Drug List (PDL)*
Ambrisentan (Letairis and Opsumit)
Wednesday, April 8, 2015 4 P.M
1 Continue Until the Day Before the Operation, but Hold on Day of Surgery
Volibris, INN-Ambrisentan
Endothelin ETA Receptor Blockade, by Activating ETB Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retention S
Advanced Control Specialty Formulary® Is a Guide Within Select Therapeutic Categories for Clients, Plan Members and Health Care Providers
Therapeutic Drug Class
E-Binder March 2021
Distinct ETA Receptor Binding Mode of Macitentan As Determined by Site Directed Mutagenesis
Top View
2020 Complete Drug List (Formulary)
NEW--Npf-MASTER LIST.Xlsx
Brand Generic Guide
Blue Cross and Blue Shield October 2019 Multi-Tier Basic Drug List I How to Use This List Generic Drugs Are Shown in Lower-Case Boldface Type
Medicaid Health Plan Common Formulary
Final Decisions and Reasons for Decisions by Delegates of the Secretary to the Department of Health
Pulmonary Arterial Hypertension: Role of Ambrisentan
FEP 5 Tier Rx Drug Formulary (607) Standard Option
Clinical Trials with Endothelin Receptor Antagonists: What Went Wrong and Where Can We Improve?☆
Drug Coverage Guidelines – Oxford Clinical Policy
Endothelin Receptor Antagonists (Eras) Annual Review Date: Tracleer (Bosentan) 1/21/2021 Letairis (Ambrisentan) Opsumit (Macitentan) Last Revised Date: 2/18/2021
SAFE HANDLING of HAZARDOUS DRUGS Updated 5/22/2020
Read the Notice
Clinical Trials with Endothelin Receptor Antagonists: What Went Wrong and Where Can We Improve?☆
Liver Toxicity of Sitaxentan in Pulmonary Arterial Hypertension
2021 Aetna Specialty Drug List
January 13, 2020
Preferred Brand Drugs with Non-Preferred Generic Drugs PDL
Ambrisentan, an Endothelin Receptor Type A-Selective Antagonist, Inhibits
Clinical Trial Protocol TITLE PAGE
Quantity Limits — Select
CVS Caremark® Value Formulary Effective As of 07/01/2021
Macitentan for the Treatment of Pulmonary Arterial Hypertension: a Review of the Literature for the Recently Approved Endothelin Receptor Antagonist
P&T Committee Meeting Minutes GHP Family November 21
Pulmonary Arterial Hypertension EOCCO POLICY
Pharmacy Passages
Performance Drug List - Standard Control
Proposed Formulary Changes Kentucky Medicaid Effective 7/1/2017
Simultaneous LC-MS Analysis of Plasma Concentrations of Sildenafil, Tadalafil, Bosentan, Ambrisentan, and Macitentan in Patients with Pulmonary Arterial Hypertension
Letairis (Ambrisentan) Tablets, for Oral Use • Idiopathic Pulmonary Fibrosis (4.2) Initial U.S
A Network Meta-Analysis for Safety of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension
Journal of Pharmaceutical and Biomedical Analysis 150 (2018) 427–435
2021 3-Tier Covered Drugs
Third Quarter 2017
Endothelin Antagonists
Medication Guide Letairis® (Le-TAIR-Is) (Ambrisentan) Tablets Read This Medication Guide Before You Start Taking Letairis and Each Time You Get a Refill
Produced by the Njarðarson Group at the University of Arizona
To: Healthpartners Clinics and Contract Medical Group Providers Healthpartners Pharmacies and Contract Pharmacies
2020 List of Covered Drugs (Formulary)
Pulmonary Arterial Hypertension and Pulmonary Fibrosis: Targeted Therapies to Improve Outcomes